Press Releases for MYL

Press Releases
PicksThatMove.com Announces Investment Opinion On: Mylan Laboratories Inc., Suncor Energy Inc., Romarco Minerals Inc., Nord Resources Corporation and Eastern Platinum Limited
Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit Against Generic Filer for Patent Infringement
Audit Integrity Announces Results of Corporate Bankruptcy Study; Identifies Companies Most Likely to Declare Bankruptcy
Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
Dey Issues Advisory
Mylan Files Lawsuit Against Pittsburgh Post-Gazette
Mylan's Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
Mylan Receives FDA Approval for Generic Version of Migraine Treatment Imitrex(R)
President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
Mylan Announces Enhancements to Executive Management Team
Mylan Reports That the FDA Determined That All Accusations Were Unfounded
Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Mylan Declares Quarterly Preferred Stock Dividend
Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
Mylan Announces Strategic Collaboration With Biocon to Enter the Global Generic Biologics Market
Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Mylan's Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
Mylan Announces Successful Matrix Delisting Offer
Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
Mylan Names Jolene Varney Chief Financial Officer
Perforomist(R) Inhalation Solution Data in Patients With Moderate to Severe COPD to Be Presented at the International Conference of the American Thoracic Society
Dey, L.P. Highlights Perforomist(R) Inhalation Solution Data to Be Presented at the International Conference of the American Thoracic Society
Semi-Annual Changes to the NASDAQ Biotechnology Index
Mylan Announces Change in Board Leadership
Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
Mylan Reports Adjusted Diluted EPS of $0.33 for the Quarter Ended March 31, 2009
Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
Mylan Declares Quarterly Preferred Stock Dividend
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
Beacon Equity Issues Trade Alerts on Newsworthy Market Movers: PHM, STZ, FDO, RPM, MYL, PLD
Mylan Announces Clarinex(R) Settlement Agreement
Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
TheFortuneFinancial.Com Initializes Free Analyst Research on MYL, CAM, SAP and CYT
Zacks Releases New Stock Picks From the +35.2% Momentum Strategy: Kirkland's Inc., Buffalo Wild Wings Inc., Allied World Assurance Holdings Ltd, Cubic Corp. And Mylan Inc.
Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
Quarterly Changes to the NASDAQ Q-50 Index
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Zacks Return On Equity Strategy Highlights: Amtrust Financial Services Inc., Mylan, Inc., Monro Muffler Brake Inc. And Cubic Corp.
Zacks Releases New Stock Picks From the +35.2% Momentum Strategy: Cubic Corp., Mylan Inc., NetScout Systems, Inc. And Matrixx Initiatives, Inc.
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Mylan Inc. (MYL) Vice Chairman and Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
Mylan Declares Quarterly Preferred Stock Dividend - Jan 29 2009 3:21PM
Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
NASDAQ Announces 2008 New Listings Statistics
U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Dey L.P. Settles State of Mississippi Pricing Litigation
Mylan's Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
Zacks Analyst Blog Highlights: Mylan, Inc., Reddy Ice Holdings, Inc., National Semiconductor Corp., Pfizer, Inc. And Jamba, Inc.
Mylan Announces Move to NASDAQ Stock Market
Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Mylan Confirms First-to-File Patent Challenge Relating to AMRIX(R)
Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
Zacks PEG Ratio Strategy Highlights: Deckers Outdoor, Mylan, Interactive Brokers Group and Perfect World
Mylan's Dey L.P. Announces Establishment of 'J-Code' for Perforomist(TM) Inhalation Solution
Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
Mylan Declares Quarterly Preferred Stock Dividend - Oct 30 2008 12:18PM
Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
Mylan's Matrix First-to-File on Generic Version of Vfend(R) Antifungal
New Data on Perforomist(TM) Inhalation Solution to be Presented at CHEST 2008
Mylan Receives Tentative FDA Approval for First-to-File Generic Version of Blood Pressure Drug Benicar HCT(R)
Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
Mylan Schedules Third Quarter Financial Results Conference Call and Live Webcast
Mylan Announces $500 Million of Floating Rate Debt Swapped to Fixed Rates
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Parcopa(R) ODT
Zacks Analyst Blog Highlights: Willis Group Holdings Ltd., Barrick Gold Corp., CSX Corp., Hess Corp. And Mylan, Inc. - Sep 22 2008 4:15PM
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
Mylan Completes $575 Million Cash Convertible Note Offering, Including Exercise of Overallotment Option
Mylan Prices $500 Million Cash Convertible Notes due 2015
Mylan to Offer $400 Million in Cash Convertible Notes
Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne(R) Tablets
Mylan Named Manufacturer of the Year by AmerisourceBergen Corporation
Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
Mylan Creates New Women's Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
Mylan Declares Quarterly Preferred Stock Dividend - Jul 31 2008 4:39PM
Mylan Acquires Remaining Interest in Somerset Joint Venture From Watson
MINRAD Announces Three Regulatory Approvals
Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
Mylan Wins Generic Prilosec(R) Patent Litigation
Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
Mylan Announces Final FDA Approval for Zaleplon Capsules